Ex-OpenAI Researcher Miles Wang Plans $2B AI Drug Discovery Startup
OpenAI researcher Miles Wang is leaving to start an AI drug discovery company, reportedly in talks to raise $200M at a $2B valuation led by Lightspeed.
Miles Wang, an OpenAI researcher who worked on using AI to speed up scientific and biological discovery, is departing to launch a new AI drug discovery startup, according to four people familiar with his plans. The company is reportedly in talks to raise around $200 million at a $2 billion valuation, with Lightspeed in discussions to lead the round. Wang disputed the reported figures and description of the company but did not provide corrected details. Several other OpenAI researchers are expected to join the venture.
What happened
| Detail | Fact |
|---|---|
| Founder | Miles Wang, OpenAI researcher |
| Target raise | ~$200 million |
| Reported valuation | $2 billion |
| Prospective lead investor | Lightspeed |
| Wang joined OpenAI | 2024 |
| Previous background | Harvard CS (dropped out) |
Miles Wang is leaving OpenAI to start a company building AI models for drug discovery, according to four sources with knowledge of his plans reported by TechCrunch. Talks about funding are still ongoing, and Wang himself disputed the reported valuation and company description without providing alternative figures.
Two sources told TechCrunch the startup may concentrate on drug repurposing: finding new medical applications for drugs that are already FDA-approved or that previously failed in clinical trials. Because those compounds have already cleared safety testing, they can reach the market much faster than a completely new molecule developed from scratch.
Why it matters: a crowded but well-funded space
Wang’s move is not happening in isolation. The same week the story broke, Chai Discovery, a two-year-old startup building AI models to predict how molecules interact and identify new drug candidates, closed a $400 million round at a $3.8 billion valuation. Its co-founder Josh Meier is also an OpenAI alumnus. Earlier, in May, Isomorphic Labs, which spun out of Google DeepMind and also works on AI-driven drug discovery, raised a $2.1 billion Series B.
That is roughly $2.7 billion flowing into the AI drug discovery space in just a couple of months, which tells you something about where venture capital is pointing right now. Investors appear willing to bet large on the idea that AI can compress the notoriously slow and expensive drug development pipeline.
Wang co-authored research at OpenAI on how AI models can automate and accelerate scientific discovery. That background, combined with the reported involvement of additional OpenAI researchers, suggests the new company would have serious technical depth from day one. For context on how quickly this generation of researchers is moving, Wang joined OpenAI in 2024 fresh from dropping out of a Harvard computer science program.
Our take
The numbers here are striking: a $2 billion valuation before a product has been announced, for a company that may not even have a final name yet. That is a bet on people and a thesis, not on proven results. Drug repurposing is a genuinely interesting angle because the regulatory runway is shorter, but “faster than drug development from scratch” still means years of clinical work and significant capital burn.
For businesses outside biotech, the takeaway is more about direction than detail. The talent flow out of frontier AI labs into applied science startups is accelerating. OpenAI and similar organizations are effectively training the next generation of founders, and those founders are leaving earlier and with bigger backing than before. If you are watching where AI capability is heading next, life sciences is clearly one of the main answers right now. You can follow coverage of this and related AI funding stories on Lumien’s AI news feed.
The wave of AI tools being built for narrow, high-value professional domains, whether drug discovery, legal research, or engineering, mirrors what we see when businesses ask about integrating AI into their own workflows. The pattern is the same: find the slow, expensive process, apply a model trained on domain-specific data, and compress the timeline. The hard part is always the domain data, not the model.
What to watch next
- Watch for a formal funding announcement from Wang’s startup, which will confirm or revise the $200M and $2B figures.
- Track which other OpenAI researchers join the company as a signal of its technical direction.
- Monitor whether the startup files any regulatory paperwork that reveals its specific drug repurposing targets.
- Note Lightspeed’s portfolio moves in biotech-AI more broadly, since their involvement signals a thesis, not just a one-off bet.
The funding talks are still live and details could change, so treat the numbers as directional until a closing is announced.
Frequently asked questions
Who is Miles Wang from OpenAI?
Miles Wang is an OpenAI researcher who worked on using AI to accelerate scientific and biological discovery. He joined OpenAI in 2024 after dropping out of a Harvard computer science program and co-authored research on how AI models can automate scientific discovery.
How much is Miles Wang's AI drug discovery startup raising?
According to two sources cited by TechCrunch, the startup is in talks to raise approximately $200 million at a $2 billion valuation, with Lightspeed in discussions to lead the round. Wang disputed these figures but did not provide alternatives. The deal is not final.
What does an AI drug repurposing startup do?
An AI drug repurposing startup uses machine learning models to identify new medical uses for drugs that are already FDA-approved or that previously failed clinical trials. Because safety testing is already done, repurposed drugs can reach the market faster than entirely new compounds.
How much money has been raised for AI drug discovery in 2026?
Chai Discovery raised $400 million at a $3.8 billion valuation, and Isomorphic Labs raised a $2.1 billion Series B in May 2026. Miles Wang's startup is reportedly in talks to raise a further $200 million, putting the sector total at roughly $2.7 billion across these three deals alone.
